Acumen Pharmaceuticals Stock Alpha and Beta Analysis
| ABOS Stock | USD 0.98 0.01 1.01% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Acumen Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Acumen Pharmaceuticals over a specified time horizon. Remember, high Acumen Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Acumen Pharmaceuticals' market risk premium analysis include:
Beta 1 | Alpha (0.65) | Risk 3.9 | Sharpe Ratio (0.24) | Expected Return (0.94) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Acumen |
Acumen Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Acumen Pharmaceuticals market risk premium is the additional return an investor will receive from holding Acumen Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acumen Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Acumen Pharmaceuticals' performance over market.| α | -0.65 | β | 1.00 |
Acumen Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Acumen Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Acumen Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Acumen Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Acumen Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Acumen Pharmaceuticals shares will generate the highest return on investment. By understating and applying Acumen Pharmaceuticals stock market price indicators, traders can identify Acumen Pharmaceuticals position entry and exit signals to maximize returns.
Acumen Pharmaceuticals Return and Market Media
The median price of Acumen Pharmaceuticals for the period between Sun, Jan 5, 2025 and Sat, Apr 5, 2025 is 1.39 with a coefficient of variation of 16.06. The daily time series for the period is distributed with a sample standard deviation of 0.23, arithmetic mean of 1.41, and mean deviation of 0.19. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 3219 shares by Siemers Eric of Acumen Pharmaceuticals at 1.59 subject to Rule 16b-3 | 01/21/2025 |
2 | Disposition of 28902 shares by Matt Zuga of Acumen Pharmaceuticals at 1.7173 subject to Rule 16b-3 | 01/23/2025 |
3 | Acumen Pharmaceuticals to Present During International Conference on Alzheimers and Parkinsons Diseases 2025 and American Academy of Neurology Annual Meeting | 03/12/2025 |
4 | Acquisition by Barton Russell of 120200 shares of Acumen Pharmaceuticals subject to Rule 16b-3 | 03/14/2025 |
5 | Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimers | 03/18/2025 |
6 | Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation ... | 03/19/2025 |
7 | Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 | 03/20/2025 |
8 | Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimers Disease | 03/26/2025 |
9 | Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024and Business Highlights | 03/27/2025 |
10 | Q4 2024 Acumen Pharmaceuticals Inc Earnings Call Transcript | 03/28/2025 |
11 | Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors | 04/01/2025 |
12 | Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at ADPD 2025 and AAN Annual Meet... | 04/02/2025 |
About Acumen Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Acumen or other stocks. Alpha measures the amount that position in Acumen Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.002586 | 0.55 | 0.3 | Revenue Per Share | 0.0423 | 0.0411 | 0.0429 |
Acumen Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Acumen Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Acumen Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Acumen Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Acumen Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Acumen Pharmaceuticals' management manipulating its earnings.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Acumen Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.